{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:13:33Z","timestamp":1793776413618,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Benign prostatic hyperplasia (BPH) is a common male urological disease around the world. This study aimed to evaluate global, regional, and national burden of BPH from 1990 to 2021, and to forecast the incidence and prevalence of BPH to 2035.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using the data and methods of the Global Burden of Disease 2021, we presented the incidence, prevalence, and disability-adjusted life-years (DALYs) of BPH from 1990 to 2021. The trends of burden over time were assessed using estimated annual percentage changes. We applied Bayesian age-period-cohort model to forecast the incidence and prevalence of BPH to 2035.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In 2021, the global number of incident cases, prevalent cases, and DALYs of BPH were 137.88, 1125.02, and 22.36 per 100,000 populations, respectively. From 1990 to 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALYs rate (ASDR) of BPH remained stable. The highest ASIR, ASPR, and ASDR were recorded in Eastern Europe in 2021. Nationally, China had the highest number of incident cases, prevalent cases, and DALYs of BPH. With the increase of socio-demographic index, the trends of ASIR, ASPR, and ASDR all exhibit an initial rise followed by a gradual decline. The global incidence and prevalence are expected to increase from 962.42 to 7878.68 per 100,000 populations in 2022 to 998.55 and 8620.60 per 100,000 populations in 2035, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The persistent burden of BPH continues to pose a critical public health challenge. The escalating prevalence among middle-aged and elderly populations underscores the imperative to tackle this widespread condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12894-025-01715-9","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:29:50Z","timestamp":1739953790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035"],"prefix":"10.1186","volume":"25","author":[{"given":"Hui","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"1715_CR1","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/nrdp.2016.31","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Reviews Disease Primers. 2016;2:16031.","journal-title":"Nat Reviews Disease Primers"},{"issue":"1","key":"1715_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11\u20139.","journal-title":"J Urol"},{"issue":"3","key":"1715_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with lower urinary tract symptoms: Prevalence and Incident Rates. Urologic Clin North Am. 2016;43(3):289\u201397.","journal-title":"Urologic Clin North Am"},{"issue":"4","key":"1715_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bju.12745","volume":"115","author":"M Speakman","year":"2015","unstructured":"Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508\u201319.","journal-title":"BJU Int"},{"issue":"2","key":"1715_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","volume":"59","author":"G Welch","year":"2002","unstructured":"Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health professionals follow-up study. Urology. 2002;59(2):245\u201350.","journal-title":"Urology"},{"key":"1715_CR6","doi-asserted-by":"crossref","unstructured":"Park S, Ryu JM, Lee M. Quality of life in older adults with Benign Prostatic Hyperplasia. Healthc (Basel Switzerland). 2020;8(2).","DOI":"10.3390\/healthcare8020158"},{"issue":"1","key":"1715_CR7","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-017-06628-8","volume":"7","author":"SWH Lee","year":"2017","unstructured":"Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7(1):7984.","journal-title":"Sci Rep"},{"issue":"6","key":"1715_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.15286","volume":"127","author":"BM Launer","year":"2021","unstructured":"Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127(6):722\u20138.","journal-title":"BJU Int"},{"issue":"4","key":"1715_CR9","doi-asserted-by":"publisher","first-page":"155798832110367","DOI":"10.1177\/15579883211036786","volume":"15","author":"XF Xu","year":"2021","unstructured":"Xu XF, Liu GX, Guo YS, Zhu HY, He DL, Qiao XM, et al. Global, Regional, and National Incidence and Year lived with disability for Benign Prostatic Hyperplasia from 1990 to 2019. Am J Men\u2019s Health. 2021;15(4):15579883211036786.","journal-title":"Am J Men\u2019s Health"},{"issue":"12","key":"1715_CR10","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1007\/s00345-023-04658-8","volume":"41","author":"D Liu","year":"2023","unstructured":"Liu D, Li C, Li Y, Zhou L, Li J, Wang Y, et al. Benign prostatic hyperplasia burden comparison between China and United States based on the global burden of Disease Study 2019. World J Urol. 2023;41(12):3629\u201334.","journal-title":"World J Urol"},{"key":"1715_CR11","unstructured":"GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia. lancet Healthy Longev. 2022;3(11):e754\u201376. in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019."},{"issue":"1","key":"1715_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40779-021-00359-8","volume":"8","author":"C Zhu","year":"2021","unstructured":"Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Military Med Res. 2021;8(1):64.","journal-title":"Military Med Res"},{"key":"1715_CR13","doi-asserted-by":"crossref","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of Disease Study 2021. Lancet (London England). 2024;403(10440):2133\u201361.","DOI":"10.1016\/S0140-6736(24)00757-8"},{"key":"1715_CR14","unstructured":"GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of Disease Study 2021. Volume 403. Lancet; 2024. pp. 1989\u20132056. (London, England). 10440."},{"issue":"10","key":"1715_CR15","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41591-022-01990-1","volume":"28","author":"CJL Murray","year":"2022","unstructured":"Murray CJL. The global burden of Disease Study at 30 years. Nat Med. 2022;28(10):2019\u201326.","journal-title":"Nat Med"},{"key":"1715_CR16","doi-asserted-by":"crossref","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of Disease Study 2021. Lancet (London England). 2024;403(10440):2100\u201332.","DOI":"10.1016\/S0140-6736(24)00367-2"},{"issue":"1","key":"1715_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40779-021-00354-z","volume":"8","author":"H Zi","year":"2021","unstructured":"Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990\u20132019. Military Med Res. 2021;8(1):60.","journal-title":"Military Med Res"},{"issue":"1","key":"1715_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1186\/s12885-022-10244-9","volume":"22","author":"Q Huang","year":"2022","unstructured":"Huang Q, Zi H, Luo L, Li X, Zhu C, Zeng X. Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030. BMC Cancer. 2022;22(1):1164.","journal-title":"BMC Cancer"},{"issue":"3","key":"1715_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/bimj.201500263","volume":"59","author":"A Riebler","year":"2017","unstructured":"Riebler A, Held L. Projecting the future burden of cancer: bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biometrical J Biometrische Z. 2017;59(3):531\u201349.","journal-title":"Biometrical J Biometrische Z"},{"issue":"1","key":"1715_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mcna.2010.08.013","volume":"95","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am. 2011;95(1):87\u2013100.","journal-title":"Med Clin N Am"},{"issue":"3","key":"1715_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1517\/13543784.2013.761973","volume":"22","author":"S Gravas","year":"2013","unstructured":"Gravas S, de la Rosette JJ. Investigational therapies targeted to the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2013;22(3):357\u201368.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1715_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ucl.2021.07.007","volume":"49","author":"D Elterman","year":"2022","unstructured":"Elterman D, Gao B, Lu S, Bhojani N, Zorn KC, Chughtai B. New technologies for treatment of Benign Prostatic Hyperplasia. Urologic Clin North Am. 2022;49(1):11\u201322.","journal-title":"Urologic Clin North Am"},{"issue":"1","key":"1715_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40779-024-00533-8","volume":"11","author":"SY Wang","year":"2024","unstructured":"Wang SY, Cai Y, Hu X, Li F, Qian XH, Xia LY, et al. P. Gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6\/IL-6R pathway. Military Med Res. 2024;11(1):30.","journal-title":"Military Med Res"},{"issue":"3","key":"1715_CR24","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/med.21778","volume":"41","author":"C Fang","year":"2021","unstructured":"Fang C, Wu L, Zhu C, Xie WZ, Hu H, Zeng XT. A potential therapeutic strategy for prostatic disease by targeting the oral microbiome. Med Res Rev. 2021;41(3):1812\u201334.","journal-title":"Med Res Rev"},{"issue":"3","key":"1715_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/agm2.12331","volume":"7","author":"Q Huang","year":"2024","unstructured":"Huang Q, Li BH, Wang YB, Zi H, Zhang YY, Li F, et al. Clinical biomarker-based biological aging and risk of benign prostatic hyperplasia: a large prospective cohort study. Aging Med (Milton (NSW)). 2024;7(3):393\u2013405.","journal-title":"Aging Med (Milton (NSW))"},{"key":"1715_CR26","doi-asserted-by":"publisher","first-page":"1280628","DOI":"10.3389\/fmicb.2023.1280628","volume":"14","author":"XP Guo","year":"2023","unstructured":"Guo XP, Yang J, Wu L, Fang C, Gu JM, Li F, et al. Periodontitis relates to benign prostatic hyperplasia via the gut microbiota and fecal metabolome. Front Microbiol. 2023;14:1280628.","journal-title":"Front Microbiol"},{"issue":"1","key":"1715_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40779-022-00373-4","volume":"9","author":"LY Li","year":"2022","unstructured":"Li LY, Han J, Wu L, Fang C, Li WG, Gu JM, et al. Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats. Military Med Res. 2022;9(1):12.","journal-title":"Military Med Res"},{"issue":"1","key":"1715_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12967-022-03722-y","volume":"20","author":"YB Wang","year":"2022","unstructured":"Wang YB, Yang L, Deng YQ, Yan SY, Luo LS, Chen P, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable mendelian randomization study. J Translational Med. 2022;20(1):495.","journal-title":"J Translational Med"},{"issue":"4","key":"1715_CR29","doi-asserted-by":"publisher","first-page":"155798831987038","DOI":"10.1177\/1557988319870382","volume":"13","author":"BH Li","year":"2019","unstructured":"Li BH, Deng T, Huang Q, Zi H, Weng H, Zeng XT. Body Mass Index and risk of prostate volume, International Prostate Symptom Score, maximum urinary Flow Rate, and post-void residual in Benign Prostatic Hyperplasia patients. Am J Men\u2019s Health. 2019;13(4):1557988319870382.","journal-title":"Am J Men\u2019s Health"},{"issue":"2","key":"1715_CR30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.juro.2008.10.025","volume":"181","author":"ET Kok","year":"2009","unstructured":"Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol. 2009;181(2):710\u20136.","journal-title":"J Urol"},{"issue":"1","key":"1715_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1464-410X.2011.10250.x","volume":"109","author":"SP Stroup","year":"2012","unstructured":"Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int. 2012;109(1):84\u20137.","journal-title":"BJU Int"},{"issue":"4","key":"1715_CR32","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/01.ju.0000155709.37840.fe","volume":"173","author":"JT Wei","year":"2005","unstructured":"Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256\u201361.","journal-title":"J Urol"},{"issue":"4","key":"1715_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1464-410x.1999.00966.x","volume":"83","author":"P Trueman","year":"1999","unstructured":"Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed \u2018benign prostatic hyperplasia\u2019, and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83(4):410\u20135.","journal-title":"BJU Int"},{"key":"1715_CR34","first-page":"q1126","volume":"385","author":"J Wise","year":"2024","unstructured":"Wise J. Global life expectancy to increase by almost five years by 2050, study predicts. BMJ (Clinical Res ed). 2024;385:q1126.","journal-title":"BMJ (Clinical Res ed)"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01715-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:29:57Z","timestamp":1739953797000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01715-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01715-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}